IQVIA HOLDINGS INC (IQV) Stock News
NYSE:IQV - New York Stock Exchange, Inc. - US46266C1053 - Common Stock - Currency: USD
IQV Latest News, Press Relases and Analysis
IQVIA Unveils New Custom AI Agents with NVIDIA
IQVIA Holdings Inc. (NYSE:IQV) is one of the most undervalued NYSE stocks to buy now. On June 11, IQVIA unveiled new custom-built AI agents at GTC Paris. These AI agents are developed in collaboration with NVIDIA Corp. (NASDAQ:NVDA) and are designed to streamline workflows and accelerate insights within the life sciences sector. The initiative represents […]
Mentions: NVDA
IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025
Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect.
President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy.
IQVIA Launches New AI Agents for Life Sciences and Healthcare
BofA Maintains Hold Rating on PVH Corp. (PVH), Sets $86 PT
In a report released on June 4, BofA analyst Christopher Nardone maintained a Hold rating on PVH Corp. (NYSE:PVH) with a price target of $86.00. The rating update followed the company’s release of its fiscal Q1 2025 results on the same day, with revenue growing 2% to $1.984 billion compared to the same period last […]
Doximity Declines 4.4% in a Month: How to Play the Stock Now?
DOCS slips 4.4% in a month despite strong Q4 results, margin gains and raised guidance -- is there a buying opportunity?
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday
We recently published a list of Investors Are Dumping These 10 Stocks. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other worst-performing stocks on Wednesday. Summit Therapeutics dropped its share prices by 5.14 percent on Wednesday to finish at $19.56 apiece as investors booked early profits […]
IQVIA Announces Pricing of Senior Notes
IQVIA Announces Offering of Senior Notes
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
/PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
Mentions: RNTX
